Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anebulo Pharmaceuticals, Inc.

1.71
+0.280019.58%
Post-market: 1.68-0.0299-1.75%19:47 EDT
Volume:46.21K
Turnover:73.66K
Market Cap:70.25M
PE:-5.87
High:1.71
Open:1.43
Low:1.36
Close:1.43
Loading ...

Company Profile

Company Name:
Anebulo Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
3
Office Location:
1017 Ranch Road 620 South,Suite 107,Lakeway,Texas,United States
Zip Code:
78734
Fax:
- -
Introduction:
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Directors

Name
Position
Joseph F. Lawler
Director and Chairman of the Board
Richard Anthony Cunningham
Chief Executive Officer and Director
Areta Kupchyk
Director
Aron R. English
Director
Bimal Shah
Director
Jason M. Aryeh
Director
Kenneth Lin
Director
Nat Calloway
Director

Shareholders

Name
Position
Richard Anthony Cunningham
Chief Executive Officer and Director
Daniel George
Part time Chief Financial Officer
Joseph F. Lawler
Director and Chairman of the Board
Kenneth C. Cundy
Chief Scientific Officer